Uttar Pradesh Government holds a successful ‘Pharma Conclave’ in Hyderabad

Hyderabad, January 18, 2024: The Government of Uttar Pradesh, in collaboration with the Bulk Drugs Manufacturers’ Association of India (BDMAI) and the Indian Drug Manufacturers Association (IDMA) – Telangana and Andhra Pradesh chapter, successfully organized a Pharma Conclave in Hyderabad. The event aimed to showcase Uttar Pradesh as a promising hub for investments in the pharma, drug and medical tech sectors.

The conclave witnessed the active participation of over 100 key industry leaders, distinguished speakers, government officials, scientists, and entrepreneurs. Dr. G.N. Singh, advisor to Hon’ble Chief Minister of Uttar Pradesh, welcomed the attendees and set the stage for insightful discussions on the opportunities available in Uttar Pradesh. He also highlighted the key focus areas of the Government of UP, including the upcoming ‘Promote Pharma Initiative’, establishing R&D centers, focusing on clinical trials.

The Chief Executive Officer (CEO) of Invest UP, Abhishek Prakashhighlighted the significance of Uttar Pradesh and its endeavors to create a favorable destination for investments in the pharma sector and provided insights into the investor-friendly industry landscape in the state, its robust infrastructure and key policy highlights, such as the UP Industrial Policy, FDI Policy, and Pharma Policy.

CEO of UPState Industrial Development Authority (UPSIDA), MayurMaheshwari emphasized the potential of the Bulk Drug Park in Lalitpur and Med-Tech Park in the Yamuna Expressway Industrial Development Authority (YEIDA) region and informed industry leaders about the land banks available across Uttar Pradesh for setting up industries.

Awanish Kumar Awasthi, advisor to Hon’ble Chief Minister, UP, shared the state government's vision of becoming a USD 1 Trillion economy and briefed the senior dignitaries from the Government of Telangana and the pharma industry about the conducive environment that Uttar Pradesh offers for the growth of the sector.

Speaking at the event, Dr. Krishna Ella, CMD Bharat Biotech spoke about how Uttar Pradesh could emerge as a significant pharma center by focusing on clinical trials, intermediaries, and specialty chemicals, while Dr. VenkatJasti, Chairman & CEO of Suven Life Sciences Limited discussed the challenges in the pharma industry and emphasized on the importance of infrastructure, including common effluent treatment plants and maintaining ‘no habitat zones’ in proximity to these projects.  Rajiv N of NATCO Pharma expressed interest in establishing labs in the Noida region of UP.

The Government of UP delegation also recognized the pivotal role of industry experts and the importance of appointing them as brand ambassadors of the pharma sector in southern India to attract the right kind of investments.

Prominent dignitaries, who attended the conclave, included R K Agrawal, National President of Bulk Drug Manufacturers Association, J Rajamouli, Chairman, Telangana State Board of the Indian Drug Manufacturers' Association, Dr. A Ramkishan, Deputy Drug Controller (India), CDCSO, Dr. J.A.S. Giri, Chairman, Sangfroid Industries, Dr P P Lal Krishna, Managing Director, Ramky Pharma City and VB Kamal Hassan Reddy, Director General of Drugs Control, Telangana.